Management of breast cancer—Part IIBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a540 (Published 11 July 2008) Cite this as: BMJ 2008;337:a540
- Nicholas C Turner, oncologist12,
- Alison L Jones, oncologist23
- 1Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
- 2Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London
- 3University College London Hospitals NHS Foundation Trust, London
- Correspondence to: N C Turner
Adjuvant systemic therapy has substantially reduced breast cancer mortality
For oestrogen receptor positive cancers, aromatase inhibitors are more effective than tamoxifen in postmenopausal women
Chemotherapy substantially improves the survival of selected patients
Commercially available molecular tests may further refine selection of patients for chemotherapy, and validation studies are under way
Breast cancer comprises a spectrum of related but different cancer subtypes, which have different causal genetic changes, may follow different clinical courses, and require different treatments tailored to the phenotype (fig 1⇓). Here, in this second part of our review on breast cancer, we discuss the recent advances in the systemic therapy of breast cancer, and the current drive to individualise treatment according to patient and tumour factors.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial